Audited Financial Results for the half year and year ended March 31, 2206
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lalchandani Labs reported FY26 revenue of Rs. 418.58 lacs, down about 6% from Rs. 445.38 lacs in FY25. The company showed a reported profit after tax of Rs. 6.35 lacs, but this is entirely because of a one-time gain of Rs. 61.08 lacs from a settlement (OTS) with banks and NBFCs that had classified its loans as NPAs. Stripping this out, the business actually made a loss of Rs. 51.31 lacs before tax, compared to a profit of Rs. 28.08 lacs last year. Operating cash flow turned sharply negative at Rs. (76.46) lacs versus Rs. 44.30 lacs previously. The auditor issued a qualified opinion, flagging that the company's accounts are NPA, statutory dues like PF, ESIC and TDS have not been paid since July 2024, gratuity and leave liabilities are not provisioned, balance confirmations are missing, and no provision has been made for doubtful receivables despite long ageing. The monitoring agency for the Rights Issue proceeds was also changed from Infomerics to Brickwork Ratings.
This is a red-flag filing. The headline profit is misleading because it comes from a one-time loan waiver, while the core diagnostic business is loss-making with negative operating cash flow. Unpaid statutory dues, NPA-tagged loans and a qualified auditor opinion raise serious going-concern doubts; retail investors should treat this stock with high caution.